Zhao Qiang, Tianjin Medical University Cancer Hospital

[ad_1]

　　Zhao Qiang  Chief physician, professor, MD, doctoral supervisor State Council Government Special Allowance Expert

　　Former Chairman of the Pediatric Oncology Committee of the Chinese Anti-Cancer Association, Vice Chairman of the Pediatric Oncology Committee of the Chinese Research Association, Deputy Leader of the Oncology Group of the Pediatric Surgery Branch of the Chinese Medical Association, National Children’s Medical Center-Deputy Chairman of the Hematology-Oncology Specialty Alliance, leader of the National Neuroblastoma Collaborative Group, deputy editor-in-chief of “Chinese Journal of Pediatric Hematology and Oncology”, executive editorial board member of “Chinese Journal of Clinical Oncology”, “Chinese Journal of Pediatric Surgery” and “Journal of Clinical Pediatric Surgery” 》Editorial member, project leader of the key R&D plan of the Ministry of Science and Technology, chief scientific communication expert in the field of comprehensive diagnosis, treatment and basic research of children’s solid tumors of the China Association for Science and Technology, deputy director of the Cancer Hospital Branch of the Chinese Hospital Association, and expert of children’s malignant solid tumors of the National Health Commission Deputy Chairman of the Committee, Tianjin Expert with Outstanding Contributions, Tianjin Famous Doctor, Vice President of Tianjin Hospital Association, Vice Chairman of Tianjin Anti-Cancer Association, Leader of Tianjin Children’s Malignant Tumor (Solid Tumor) Expert Group, Tianjin Anti-Cancer Association Pediatric Former chairman of the Cancer Professional Committee and leader of the pediatric cancer specialty at Tianjin Medical University Cancer Hospital.

　　Professor Zhao Qiang is engaged in clinical and basic work on malignant solid tumors in childrenFor more than 30 years, he has done a lot of pioneering work, especially in the clinical and basic aspects of neuroblastoma. He is especially good at carrying out comprehensive treatment based on surgery for refractory neuroblastoma that occurs in multiple locations, through neoadjuvant chemotherapy. Create opportunities for radical surgical resection for advanced neuroblastoma and achieve functional resection that preserves adjacent organs. It was the first in China to carry out secondary sequential autologous stem cell transplantation to treat high-risk neuroblastoma, significantly improving its overall survival rate. In the work of the clinical NB collaborative group, NMYC gene testing technology for risk grading and bone marrow GD2 testing technology for diagnosing minimal residual disease are promoted. He has been engaged in clinical and basic work on malignant solid tumors in children for more than 30 years. In 2007, he visited MD Anderson Cancer Center in the United States. Carry out multi-center and multi-disciplinary collaboration to promote standardized diagnosis and treatment of childhood malignant tumors in China. In terms of scientific research, in the past five years, he has participated in and undertaken more than 5 projects at the provincial and ministerial level or above, and published more than 40 professional-related articles in domestic and foreign SCI and Chinese core journals. As the corresponding author, he published “Expert Consensus on the Diagnosis and Treatment of Neuroblastoma in Children” and “Expert Consensus on the Multidisciplinary Diagnosis and Treatment of Hepatoblastoma in Children” in “Chinese Pediatric Surgery”. In recent years, he has participated in the compilation of “Tumor Surgery”, “Pediatric Neuroblastoma” and other books; trained more than 20 master’s and doctoral students.

[ad_2]

Source link